根据一份提交给美国证券交易委员会（SEC）的文件显示，Supernus Pharmaceuticals公司的收购价格构成中，不仅涵盖了正在进行中的2B期临床研究，还包含了未来可能支付的里程碑款项，其总额最高可达3.5亿美元。
这一安排凸显了该笔交易对相关资产未来潜力的高度认可。里程碑付款通常与研发进程中的关键节点或未来的商业化成果挂钩，此次高达3.5亿美元的潜在支付额度，无疑为市场提供了关于该资产前景的积极信号。
根据一份提交给美国证券交易委员会（SEC）的文件显示，Supernus Pharmaceuticals公司的收购价格构成中，不仅涵盖了正在进行中的2B期临床研究，还包含了未来可能支付的里程碑款项，其总额最高可达3.5亿美元。
这一安排凸显了该笔交易对相关资产未来潜力的高度认可。里程碑付款通常与研发进程中的关键节点或未来的商业化成果挂钩，此次高达3.5亿美元的潜在支付额度，无疑为市场提供了关于该资产前景的积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.